Literature DB >> 9352738

Renal vascular lesions in lupus nephritis.

E Descombes1, D Droz, L Drouet, J P Grünfeld, P Lesavre.   

Abstract

We retrospectively studied the prevalence, histologic features, clinical correlations, and long-term outcome of the intrarenal vascular lesions of lupus nephritis (LN) in a series of 169 renal biopsies performed between 1980 and 1994 in 132 patients with systemic lupus erythematosus. The most common vascular lesions were nonspecific sclerotic changes, found in 37% of the biopsies (24% if only the cases with moderate to severe changes are considered). The other common vascular lesions were "immunoglobulin microvascular casts," found in 24% of the biopsies. Vasculitis and thrombotic microangiopathy were rare lesions and were seen in only 4 (2.4%) and 1 (0.6%) cases, respectively. Isolated sclerotic vascular changes were present in biopsies from older patients with a longer duration of LN, compared with the group with no vascular lesions, and were associated with a significantly higher prevalence of hypertension. Overall, however, the long-term renal and patient survival of this group did not differ significantly from that of the patients without vascular changes. Immunoglobulin microvascular casts (IMCs) ("lupus vasculopathy") were characterized by the presence of immunoglobulin deposition within the glomerular capillaries and small arterioles. In the present study we extensively investigated the morphologic and immunologic features of this lesion. The lesions were notable for the absence of endothelial or parietal vascular lesions and of fibrin, platelets, and leukocytes, which indicates that thrombosis is not involved in the vascular obstruction. According to our data immunoglobulin precipitation in the microvasculature seems to play a central role in the pathogenesis of this lesion, which is why we propose the term "immunoglobulin microvascular casts." In general, IMCs were associated with the most severe and active forms of diffuse proliferative lupus nephritis (World Health Organization [WHO] class IV). However our data show that, in contrast to previous studies, the long-term outcome of patients with IMCs is not worse than that of other patients with class IV LN. It may even be somewhat better, suggesting that this type of lesion may reverse with immunosuppressive therapy. In addition, we did not find any association between the presence of IMCs and the lupus anticoagulant, IgG anticardiolipin antibodies, or extrarenal vascular manifestations. Concerning vasculitis and thrombotic microangiopathy, our results confirm that their occurrence is quite rare in-lupus nephritis. The outcome of our 4 patients with vasculitis was not particularly poor, which could be related to early and/or aggressive treatment. Taken as a whole, our data confirm that the presence of active and severe forms of diffuse proliferative LN (WHO class IV) carries a worse prognosis compared with the other forms of LN. In our study, and in agreement with previous reports (23), the long-term renal survival of patients with class IV LN was significantly worse than that of patients with other forms of LN, with a 10-year renal survival of 70% compared with 85%, respectively. However our data do not support the conclusions of some previous studies that the presence of intrarenal vascular lesions is a marker of poor renal prognosis in lupus nephritis. More precisely, our data show that the somewhat poorer renal outcome observed in patients with IMCs is related to the fact that in most cases these lesions are associated with class IV lupus nephritis, and not related to the presence of the vascular lesion per se.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352738     DOI: 10.1097/00005792-199709000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  29 in total

1.  Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy.

Authors:  Chems Gharbi; Edward Bourry; Philippe Rouvier; Sabria Hacini; Ahmed Letaief; Alain Baumelou; Hassane Izzedine
Journal:  Clin Exp Nephrol       Date:  2010-06-11       Impact factor: 2.801

Review 2.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

3.  Evaluation of clinical outcomes and renal vascular pathology among patients with lupus.

Authors:  Claire Barber; Andrew Herzenberg; Ellie Aghdassi; Jiandong Su; Wendy Lou; Gan Qian; Jonathan Yip; Samih H Nasr; David Thomas; James W Scholey; Joan Wither; Murray Urowitz; Dafna Gladman; Heather Reich; Paul R Fortin
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 8.237

Review 4.  Vasculitis associated with connective tissue disorders.

Authors:  Mittie K Doyle
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

5.  Association of miRNA-145 expression in vascular smooth muscle cells with vascular damages in patients with lupus nephritis.

Authors:  Yan Ding; Wang Liao; Zhuwen Yi; Wei Xiang; Xiaojie He
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies.

Authors:  Cianna Leatherwood; Cameron B Speyer; Candace H Feldman; Kristin D'Silva; José A Gómez-Puerta; Paul J Hoover; Sushrut S Waikar; Gearoid M McMahon; Helmut G Rennke; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2019-06-11       Impact factor: 5.532

7.  Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis.

Authors:  Jing Wang; Yuan-Yuan Qi; Xue-Ping Chen; Li Ma; Li-Li Zhang; Yu Zhao; Mei Wang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

Review 8.  Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.

Authors:  G Espinosa; S Bucciarelli; R Cervera; M Lozano; J-C Reverter; G de la Red; V Gil; M Ingelmo; J Font; R A Asherson
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

9.  Lupus vasculopathy combined with acute renal failure in lupus nephritis.

Authors:  Chien-Te Wu; Lin-Shien Fu; Mei-Chin Wen; Shein-Chung Hung; Ching-Shiang Chi
Journal:  Pediatr Nephrol       Date:  2003-10-24       Impact factor: 3.714

10.  Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases.

Authors:  Hui Zheng; Yi Chen; Wen Ao; Yan Shen; Xiao-wei Chen; Min Dai; Xiao-dong Wang; Yu-cheng Yan; Cheng-de Yang
Journal:  Arthritis Res Ther       Date:  2009-06-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.